Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

BACKGROUND: Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients following progression with standard tyrosine-kinase inhibitors (TKIs), imatinib, sunitinib and regorafenib. We retrospectively collected data from metastatic Italian GIST patients treated wi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Ther Adv Med Oncol
Huvudupphovsmän: Vincenzi, Bruno, Nannini, Margherita, Badalamenti, Giuseppe, Grignani, Giovanni, Fumagalli, Elena, Gasperoni, Silvia, D’Ambrosio, Lorenzo, Incorvaia, Lorena, Stellato, Marco, Spalato Ceruso, Mariella, Napolitano, Andrea, Valeri, Sergio, Santini, Daniele, Tonini, Giuseppe, Casali, Paolo Giovanni, Dei Tos, Angelo Paolo, Pantaleo, Maria Abbondanza
Materialtyp: Artigo
Språk:Inglês
Publicerad: SAGE Publications 2018
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6116078/
https://ncbi.nlm.nih.gov/pubmed/30181783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918794623
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk